Jiangsu Lianhuan Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Jiangsu Lianhuan Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has a cash flow conversion efficiency ratio of -0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-15.07 Million ≈ $-2.21 Million USD) by net assets (CN¥1.74 Billion ≈ $254.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jiangsu Lianhuan Pharmaceutical Co Ltd (2002–2024)
Cash flow conversion efficiency of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2002 to 2024. This chart illustrates how Jiangsu Lianhuan Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Jiangsu Lianhuan Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Jiangsu Lianhuan Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Jiangsu Lianhuan Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jiangsu Lianhuan Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Lianhuan Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Goldcard High-Tech Co Ltd
SHE:300349
|
0.046x |
|
Hanwha REIT Co. Ltd.
KO:451800
|
N/A |
|
Sharda Motor Industries Limited
NSE:SHARDAMOTR
|
0.110x |
|
Elmera Group ASA
OL:ELMRA
|
0.772x |
|
Probe Gold Inc.
TO:PRB
|
-0.217x |
|
Vatti Corp Ltd
SHE:002035
|
0.032x |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
-0.017x |
|
Keeson Technology Corp Ltd
SHG:603610
|
0.060x |
Annual Cash Flow Conversion Efficiency for Jiangsu Lianhuan Pharmaceutical Co Ltd (2002–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2002 to 2024. Review Jiangsu Lianhuan Pharmaceutical Co Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.58 Billion ≈ $230.80 Million |
CN¥10.77 Million ≈ $1.58 Million |
0.007x | -93.56% |
| 2023-12-31 | CN¥1.52 Billion ≈ $222.03 Million |
CN¥160.70 Million ≈ $23.52 Million |
0.106x | +17.35% |
| 2022-12-31 | CN¥1.41 Billion ≈ $206.87 Million |
CN¥127.59 Million ≈ $18.67 Million |
0.090x | -16.44% |
| 2021-12-31 | CN¥1.28 Billion ≈ $187.44 Million |
CN¥138.34 Million ≈ $20.24 Million |
0.108x | +38.86% |
| 2020-12-31 | CN¥1.18 Billion ≈ $172.97 Million |
CN¥91.94 Million ≈ $13.45 Million |
0.078x | +954.26% |
| 2019-12-31 | CN¥1.08 Billion ≈ $158.63 Million |
CN¥-9.87 Million ≈ $-1.44 Million |
-0.009x | +90.63% |
| 2018-12-31 | CN¥946.61 Million ≈ $138.52 Million |
CN¥-92.00 Million ≈ $-13.46 Million |
-0.097x | -2447.48% |
| 2017-12-31 | CN¥878.23 Million ≈ $128.51 Million |
CN¥3.64 Million ≈ $532.06K |
0.004x | -95.13% |
| 2016-12-31 | CN¥827.25 Million ≈ $121.05 Million |
CN¥70.28 Million ≈ $10.28 Million |
0.085x | +5.99% |
| 2015-12-31 | CN¥774.88 Million ≈ $113.39 Million |
CN¥62.12 Million ≈ $9.09 Million |
0.080x | -49.91% |
| 2014-12-31 | CN¥434.25 Million ≈ $63.54 Million |
CN¥69.50 Million ≈ $10.17 Million |
0.160x | +73.13% |
| 2013-12-31 | CN¥402.11 Million ≈ $58.84 Million |
CN¥37.17 Million ≈ $5.44 Million |
0.092x | +91.22% |
| 2012-12-31 | CN¥350.42 Million ≈ $51.28 Million |
CN¥16.94 Million ≈ $2.48 Million |
0.048x | -34.00% |
| 2011-12-31 | CN¥327.61 Million ≈ $47.94 Million |
CN¥24.00 Million ≈ $3.51 Million |
0.073x | +168.56% |
| 2010-12-31 | CN¥308.95 Million ≈ $45.21 Million |
CN¥8.43 Million ≈ $1.23 Million |
0.027x | -42.05% |
| 2009-12-31 | CN¥293.89 Million ≈ $43.01 Million |
CN¥13.83 Million ≈ $2.02 Million |
0.047x | -23.99% |
| 2008-12-31 | CN¥281.68 Million ≈ $41.22 Million |
CN¥17.44 Million ≈ $2.55 Million |
0.062x | +108.09% |
| 2007-12-31 | CN¥269.97 Million ≈ $39.51 Million |
CN¥8.03 Million ≈ $1.18 Million |
0.030x | -23.97% |
| 2006-12-31 | CN¥259.20 Million ≈ $37.93 Million |
CN¥10.14 Million ≈ $1.48 Million |
0.039x | +162.08% |
| 2005-12-31 | CN¥255.97 Million ≈ $37.46 Million |
CN¥3.82 Million ≈ $559.35K |
0.015x | +10.21% |
| 2004-12-31 | CN¥250.42 Million ≈ $36.64 Million |
CN¥3.39 Million ≈ $496.50K |
0.014x | +125.29% |
| 2003-12-31 | CN¥246.22 Million ≈ $36.03 Million |
CN¥-13.19 Million ≈ $-1.93 Million |
-0.054x | -123.77% |
| 2002-12-31 | CN¥85.26 Million ≈ $12.48 Million |
CN¥19.22 Million ≈ $2.81 Million |
0.225x | -- |
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more